Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Unicycive Therapeutics, Inc. (UNCY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/13/2023 |
4
| Aggarwal Gaurav (Director) has filed a Form 4 on Unicycive Therapeutics, Inc.|
Txns:
| Converted 3,470,152 shares
@ $0
Converted 8,077 preferred shares
@ $1000, valued at
$8.1M
Converted 13,429,000 preferred shares
@ $0
Converted 12,802,388 options to buy
@ $0.539, valued at
$6.9M
Converted 11,638,534 options to buy
@ $0.5929, valued at
$6.9M
Converted 18,621,655 options to buy
@ $0.7411, valued at
$13.8M
|
|
| 07/13/2023 |
4
| Jermasek Douglas (EVP of Corporate Strategy) has filed a Form 4 on Unicycive Therapeutics, Inc.|
Txns:
| Exercised 104,612 shares
@ $0
Exercised 50 convertible preferred
@ $0.49, valued at
$24.5
Exercised 79,252 options to buy
@ $0.54, valued at
$42.8k
Exercised 72,047 warrants
@ $0.59, valued at
$42.5k
Exercised 115,275 warrants
@ $0.74, valued at
$85.3k
|
|
| 07/13/2023 |
4
| Gupta Pramod (EVP, Pharmaceuticals and BD) has filed a Form 4 on Unicycive Therapeutics, Inc.|
Txns:
| Exercised 41,845 shares
@ $0
Exercised 20 convertible preferred
@ $0.49, valued at
$9.8
Exercised 31,700 options to buy
@ $0.54, valued at
$17.1k
Exercised 28,818 warrants
@ $0.59, valued at
$17k
Exercised 46,110 warrants
@ $0.74, valued at
$34.1k
|
|
| 07/13/2023 |
4
| Gupta Shalabh K. (CEO) has filed a Form 4 on Unicycive Therapeutics, Inc.|
Txns:
| Exercised 104,612 shares
@ $0
Exercised 50 convertible preferred
@ $0.49, valued at
$24.5
Exercised 79,252 options to buy
@ $0.54, valued at
$42.8k
Exercised 72,047 warrants
@ $0.59, valued at
$42.5k
Exercised 115,275 warrants
@ $0.74, valued at
$85.3k
|
|
| 07/06/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Unicycive Therapeutics, Inc. |
| 07/06/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in UNICYCIVE THERAPEUTICS, INC. |
| 06/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/23/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/16/2023 |
8-K
| Quarterly results |
| 05/16/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/16/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/18/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 03/09/2023 |
4
| Aggarwal Gaurav (Director) has filed a Form 4 on Unicycive Therapeutics, Inc.|
Txns:
| Granted 8,077 convertible preferred
@ $1000, valued at
$8.1M
|
|
| 03/09/2023 |
4
| Gupta Shalabh K. (CEO) has filed a Form 4 on Unicycive Therapeutics, Inc.|
Txns:
| Granted 50 convertible preferred
@ $1000, valued at
$50k
|
|
| 03/09/2023 |
4
| Gupta Pramod (EVP, Pharmaceuticals and BD) has filed a Form 4 on Unicycive Therapeutics, Inc.|
Txns:
| Granted 20 convertible preferred
@ $1000, valued at
$20k
|
|
| 03/09/2023 |
4
| Jermasek Douglas (EVP of Corporate Strategy) has filed a Form 4 on Unicycive Therapeutics, Inc.|
Txns:
| Granted 50 convertible preferred
@ $1000, valued at
$50k
|
|
| 03/08/2023 |
3
| Aggarwal Gaurav (Director) has filed a Form 3 on Unicycive Therapeutics, Inc. |
| 03/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock",
"Form of Specimen Stock Certificate for Series A-1 Preferred Stock",
"Form of Tranche A Warrant",
"Form of Tranche B Warrant",
"Form of Tranche C Warrant",
"Form of Securities Purchase Agreement, by and between Unicycive Therapeutics, Inc. and the purchasers named therein",
"Placement Agency Agreement, by and between Unicycive Therapeutics, Inc. and EF Hutton, division of Benchmark Investments, LLC",
"Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb" |
|
| 03/02/2023 |
8-K
| Other Events Interactive Data |
| 02/14/2023 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 8% stake in UNICYCIVE THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 6.1% stake in UNICYCIVE THERAPEUTICS, INC. |
| 02/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 02/02/2023 |
8-K
| Quarterly results |
| 12/29/2022 |
8-K
| Quarterly results |
|
|
|